ESIC CENTRAL RATE CONTRACT NO. -143

Transcription

1 ESIC CENTRAL RATE CONTRACT NO FOR SUPPLY OF DRUGS & DRESSINGS (VALID FROM 3rd MAY, 2018 to 2"d MAY, 2020) DRUGS FOR RESPIRATORY SYSTEM DRUGS FOR CARDIO-VASCULAR SYSTEM DRUGS ACTING ON CENTRAL NERVOUS SYSTEM STRICTLY FOR OFFICIAL USE EMPLOYEES' STATE INSURANCE CORPORATION ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN C.I.G. ROAD, NEW DELHI

2 ESIC CENTRAL RATE CONTRACT NO FOR SUPPLY OF DRUGS & DRESSINGS (VALID FROM 3rd MAY, 2018 to 2"d MAY, 2020) DRUGS FOR RESPIRATORY SYSTEM DRUGS FOR CARDIO-VASCULAR SYSTEM DRUGS ACTING ON CENTRAL NERVOUS SYSTEM STRICTLY FOR OFFICIAL USE PUBLISHED BY DIRECTOR GENERAL EMPLOYEES' STATE INSURANCE CORPORATION ROOM NO. 312 & 314, HQRS. OFFICE, PANCHDEEP BHAWAN C.I.G. ROAD, NEW DELHI

3 Sno. Contents Page No. 1. Forwarding letter along with terms & I-XI conditions for operation of Rate Contract No. 139 (A). 2. List of Approved Pharmaceutical firms Address with Terms & Conditions of the 1-7 Eligible firms 4. Index Rate Schedule 1-22

4 REGISTERED STRICTLY FOR OFFICIAL USE ONLY HQRS. OFFICE EMPLOYEES' STATE INSURANCE CORPORATION PANCHDEEP BHAWAN: C.I.G. ROAD: NEW DELHI TeiFax: , (An IS :2008 Certified) No.U-25/12/142/2017-Med. V/RC 143 Dated: 3'a May, 2018 From: To The Director General, E. S.l. Corporation, Panchdeep Bhawan, C.I.G Road, NEW DELHI The Director, ESI Scheme -All States Medical Superintendent- ESIC Model Hospitals Sub PURCHASE OF DRUGS AND DRESSINGS UNDER THE E.S.I. CORPORATION CENTRALISED RATE CONTRACT NO. 143 EFFECTIVE FROM TO Sir I Madam, Please find enclosed a copy of the DG-ESIC Centralised Rate Contract finalised for supply of drugs and dressings under the ESI Scheme in the country. The rate contract will come into force with effect from the date of issue of this rate schedule, i.e, Further, the following instructions are issued to govern operation of the Rate Contract. 1. Immediately on receipt of this communication, the Chief Direct Demanding Officers (Director/Add!. Director/Jt. Director/Dy. Director/Administrative Medical Officer/Director (Medical) Delhi shall intimate the names and complete address of the officers who have been designated as Direct Demanding Officer for the purpose of operation of this Rate Contract on his behalf, to all the Rate Contract holders. The Rate Contract holders would entertain the supply orders & related correspondences from the officers working as DDOs only after the receipt of such communication from the Chief DDOs. I

5 2. The Chief DDOs may bring to the notice of the undersigned the discrepancies (especially in rate, packing, composition of the drug) if any observed by them. In case the rates of the firms approved in this Rate Contract are found to be higher than their rates in any local Rate Contract or in the market, the same may be intimated along with the documentary proof. 3. The applicability of GST may affect to some extent the rates finally approved under this Rate Contract and in such cases, orders may be placed to the firm at the lowest rates. While taking this step, the benefit of concession in rate of GST available under GST Act or the rules framed there under will be taken into account. 4. The Stores accepted should comply with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder as amended upto date and Drug Price Control Order. SUPPLIES 5. All the supply orders shall be signed only by the officers who have been duly authorised and included in the list of DDOs. DDOs will send scanned copy of the Purchase order through followed by Registered AD post directly to the firm alongwith a copy to the office of the firm situated at the respective zone. 6. It will be ensured before placing order by the Director Demanding Officer that necessary funds are available and payment of bills should be arranged expeditiously within 4-6 weeks time of the execution of the orders by the Rate Contract Holder and there should not be unnecessary delay in the payment of their bills. 7. Supply orders will be placed from time to time during the currency of the contract in which the exact quantities required on each occasion together with the date of delivery shall be specified by the Direct Demanding Officers. 8. Supply orders will be placed by Heads of ESI Scheme of various States/ Medical Superintendents, ESIC Model Hospitals, who for the purpose of this Rate Contract, shall be designated as Chief Direct Demanding Officer and will exercise the powers of Director General, ESI Corporation in all matters connected with the execution of supplies and I or wherever specifically provided in the terms & conditions of the Rate Contract. The ll

6 Chief Direct Demanding Officer can also designate any of his subordinate officer as Direct Demanding Officer (DDO) to operate this Rate Contract. 9. Supply orders against the contract will be accepted as long as these reach the contractor on or before last date of the currency of the contract. Supply orders received during the closing days should be complied within due course, in accordance with the contract if even though in some cases owing to contract having expired, supplies are to be complied with even after the expiry of the last date of the contract. 10. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the contractor I seller to supply the item as per the specifications of the relevant rate contract. 11. During transit pharmaceutical firm should maintain the recommended temperature of the drug (wherever indicated), otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled. It will be counted as a non-supply. 12. In all contracts for items/ drugs, which are branded with 'ESI SUPPLY' mark including rejected items/ drugs, it would be a condition that such items/ drugs will not be sold to the public/open market. 13. The purchaser will not pay separately for transit insurance and the contractor will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance, Octroi etc, if any, will have to be borne by the supplier. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the contractor of any loss or damage to the stores, that may have occurred during the transit. 14. Marking : Each packing shall be printed with nomenclature of the drug and shall be labelled in accordance with the requirement of the Drugs and Cosmetics Act, 1940 and the rules made there under. Packing & packaging of the each drug must comply with the procedure provided under the Legal Metrology Act, 2009 and rules made there under. III

7 15. Packing : a) It should be ensured that all labels of cartons, ampoules, vials, bottles, jars, tubes, tins, containers etc., have "For ESI supply, Not to be sold" imprinted clearly. Any consignment without such stamping will not be considered valid and will be rejected. b) Loose supplies/damaged packing/tempered or damaged labeled supplies shall not be accepted under any circumstances. c) Supplies to be made in proper boxes. d) Liquid orals to be supplied only in glass/ plastic bottles conforming to I P I Drugs & Cosmetics Act. e) Large volume parenterals to be quoted and supplied only in plastic bottles I polypacks conforming to I.P. f) It should be ensured that only first use packaging material of uniform size including Bottles and vials should be used for making supplies on the basis of ESI Rate Contract. g) All primary packing containers should be strictly conforming to the specifications described/ mentioned in the relevant pharmacopoeia. h) Packing should be able to prevent damage or deterioration during transit. i) All containers i.e. bottles, tins, cartons, tubes etc., are required to be secured with pilfer-proof seals to ensure genuineness of the products packed and the correctness of the contents. j) It should be ensured that lsi Code No. is indicated on the packing and at the time of supplies, it must be ensured that the items supplied has lsi Mark as well as Code No., as is the statutory requirement of the Bureau of Indian Standards. 16. Life Period : a) For Drugs having shelf life of Two years or less: Drug supplied should not be older than one fourth (1/4) of its shelf life from the date of manufacture. b) For Drugs having shelf life more than Two years: Drug supplied should not be older than one sixth (1/6) of its shelf life from the date of manufacture. c) For Imported Drugs: All Imported Drugs should have 50 % of shelf life from the date of manufacture at the time of supply. 17. Pharmacopoeia Specifications: Pharmacopoeia Specification IP/BP/USP etc. should be clearly mentioned against each drug/constituent of the drug supplied as per the provisions of Drug and Cosmetics Act. IV

8 18. Testing of Drugs- Quality Contro! a) Approved Rate Contract Holder should submit a Test Report that particular batch of medicines tested by the Government/ Government approved Laboratories (as per list circulated from ESIC Hqrs/ Hospitals/ State Govt. from time to time) along with each supply. b) The Chief D.D.Os may get at least 10% of the drugs tested in the Government Laboratory, or in any of the Govt. Approved laboratories, the list of which has been issued. Instructions issued in this regard Hqrs. Office from time to time may please be adhered to Details of the items found not of standard quality should be brought to the notice of the undersigned along with the test reports immediately. All such test reports should necessarily come through Chief D.D.Os only. A copy of the test report should be sent immediately to the firm, the concerned Drug controllers, and respective Central Drug Control authorities for necessary action. c) Regular and random testing of drugs will be under taken by ESI from Govt./Govt. approved laboratories at the time of supply and at any time during the shelf life or whenever any defect is noticed. The Director General, ESI Corporation shall be at liberty to undertake regular and random testing of the drugs supplied by the pharmaceutical firm/ firm at regular interval to maintain and ensure the quality of drugs. d) The report of the Govt./Govt. approved laboratory shall be accepted by the pharmaceutical firm. In case the same is disputed by the pharmaceutical firm the report of the Appellate Laboratory only will be accepted as final. However the same should be submitted within three months, from the date of communication of the disputed test report to the pharmaceutical firm. For this, the pharmaceutical firm should approach the concerned Drug Control Authorities for getting the drugs tested, as per procedure, from the Appellate Laboratory. e) If any store/stores supplied against this Rate Contract are found to be Not of standard quality on test analysis from approved laboratory and I or on inspection by competent authority, the contractor will be liable to replace the entire quantity or make full payment of entire consignment against the v

9 particular invoice irrespective of fact that part or whole of the supplied stores may have been consumed. f) If the product is found to be 'not of standard quality', the cost of testing will be recovered from the supplier. The classification of defects into different categories is as per the guidelines issued by the Drug Controller of India & action will be taken by ESIC for each category of defects. described as under:- A. CATEGORY 'A' DEFECT (Spurious I Adulterated Drugs)- lf any item I Batch of the item declared Not of Standard quality (NSQ) under Category A. Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract Debarring of the Rate Contract holder I Pharmaceutical firm from current and all future DGESIC Rate Contract for a period of five (5) years. Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drug. B. CATEGORY 'B' DEFECT.(Grossly Substandard Drugs) I. If single item/ Batch of item is declared NSQ under Category B Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract. Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract. Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of VI

10 any adverse reaction reported in the Hospital during administration of the drugs. II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category 8 within a year Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract. Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years. Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs. C CATEGORY' C' DEFECT (Minor Defects) I. If single item/ Batch of item is declared NSQ under Category C Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract. Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual/ individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs. VII

11 II. If more than one item/ Batch of item belonging to any individual pharmaceutical firm is declared NSQ under Category C within a year Recall of the NSQ item immediately from all ESIC/ ESIS User Units. Recoveries to be initiated by the DDO's wherever payment had been made already. Forfeiture of Performance Security from the respective DGESIC Rate Contract. Rate Contract Holder/ Pharmaceutical firm will be debarred for further supply of the said NSQ item in the currency of the Rate contract. Debarring of Rate Contract Holder/ Pharmaceutical firm immediately from current and all future DGESIC Rate Contracts for a period of three years Rate Contract Holder/ Pharmaceutical firm will be liable to pay damages/ compensation (if any) to individual! individuals arising due to consumption of item declared NSQ and in case of any adverse reaction reported in the Hospital during administration of the drugs. 19. Delivery Period- ~isk Purchase a. Delivery period will be six weeks. b. If the pharmaceutical firm fails to execute the supply order within the stipulated period of six weeks, a penalty of two (2) per cent of the value of the order calculated at the contract rate per week or a part of a week will be levied. The maximum penalty for late supply shall not exceed 10% of the total value of the order/orders. A pharmaceutical firm can seek extension of the delivery period with the prior consent of the Director Demanding Officers, if it is not in a position to execute the order in time. Such extension is permissible for a maximum period of 5 weeks only but penalty will be levied. That extension of delivery period cannot be claimed as a matter of right but will be at the discretion of concerned Officer. c. If the items/ drugs are not supplied by the schedule date (as indicated above or by the extended date) full or in part, the order in respect of the quantity not supplied is liable to be cancelled at the risk and expense of pharmaceutical firm. The extra expenditure involved in procuring supplies from elsewhere will, in that case, be recoverable from the vnr

12 pharmaceutical firm, in full at discretion of Direct Demanding Officers. The recoveries thus due will be deducted from any sum payable by the Direct Demanding Officer or which at any time thereafter may become payable under this contract or any other contract placed with firm by the Direct Demanding Officers. He will be deemed to be exercising the powers of Director General, ESI Corporation in case any such contingency arises. Apart from risk purchase action, the firm's the Performance security deposit may be forfeited and shall invite other penal action like debarring from participating in ESI Corporation Rate Contract present and future for a period of not less than five years. d. In case of failure to supply, the Corporation reserves the right to purchase the stocks from other sources as risk purchase, i.e. purchase from any other pharmaceutical firm or firms, in the rate contract or from outside the contract at the discretion of the Direct Demanding Officer concerned at a competitive rate. 20. Payment a. Payment may be made directly to the firm. Payment for the supply will be made within 4 to 6 weeks (after receipt and acceptance of the drugs/items) directly by the Direct Demanding Officers or through nominees to whom bills are submitted. Notwithstanding any omission or shortcoming in the supply order it is incumbent upon the pharmaceutical firm to supply the items as per the specifications of the relevant rate contract b. The price charged for the stores supplied under the agreement or the rate quoted by firm for supply of medicines to the DG-ESIC, whichever is lower, shall in no event exceed the lowest price at which the firm sells the stores of identical description to any other person(s) during the said period of agreement. If at any time during the said period, the firm reduces the sales price of such stores or sells such stores to any other person at a price lower than the price chargeable under the agreement, he shall forthwith notify such reduction in sale price to the Director General, E.S.I. Corporation and Direct Demanding Officers and the price payable under the agreement for the stores supplied after the date of its coming in to force will be the reduced price. The approved price in Rate Contract shall stand correspondingly reduced. The preference in the Rate contract will not be changed till any further fresh instructions. IX

13 c. The price must be quoted F.O.R Destination per unit as shown in the schedule annexed and should be exclusive of GST Tax but inclusive of all charges for packing and forwarding. d. GST Taxes, if extra, where legally leviable and intended to be claimed, should be distinctly shown separately alongwith the price quoted. Where this is not done, no claim of GST taxes will be admitted at any later stage and on any ground whatsoever. e. The purchaser will not pay separately for transit insurance and the firm will be responsible for delivery of items covered by the supply order in good condition at the specified destination and for this purpose freight, insurance,octroi etc., if any, will have to be borne by the firm. f. The consignee will, as soon as possible, but not later than 30 days of the date of arrival of stores at destination, notify the pharmaceutical firm, of any loss damage to the stores, that may have occurred during the transit. 21. Any dues or payments that have arisen to the Corporation from the contractor for which no specific time limit has been laid down in the terms and conditions shall be payable by the contractor within such time limit as may be prescribed in the letters I orders addressed to the contracts. 22. Any payments that have been demanded as per the provision of Clause 22 or under any other clause shall be payable within the time laid down. On failure to do so: - 1. The Contractor shall be liable to be debarred for supplying medicines I drugs etc. to the Corporation for a period not exceeding five years. ii. The contract is liable to be prosecuted in the court of law. 23. Non Supply The Chief DDOs shall monitor the performance of the Rate Contract holding firms in regard to their execution of supply orders in time. He shall send a consolidated quarterly non-supply report (in Excel format only) along with the comments and details as under:- PROFORMA FOR NON-SUPPLY REPORT R.C. Item No. & Name of S.O. No. Qty. not Risk Payment Remarks No. Name of firm with supplied Purchase/ if Drug Date penalty pending levied X

14 24. Rate Schedule along with list of item-wise finalized rates, along with name of the approved firms is enclosed. In regard to items where rates of more than one firm have been approved, order should be placed to the firm at First Preference and whose rates are the lowest. In case of non-supply by such firm, order shall be placed to the firm with the next higher approved rate invoking risk purchase. 25. No other document should be entertained for giving any cognizance for placing the supply orders. 26. Acceptance letter issued to the firms by this office cannot be used for placing orders. Receipt of this letter may please be acknowledged. Encl.: As above. Copy to: Yours faithfully, ~~;f"-/. (~Jl;em Logani) Dy. Medical Commissioner (RC) For: DIRECTOR GENERAL 1. All Chief Direct Demanding Officers (In-Charge) of ESI Scheme of all States for information and with the request to circulate this letter along with enclosures among all DDOs under their control for necessary compliance. They are also requested to send the list of DDOs to the firms approved in the Rate Contract. 2. P.S. to Director General for information of Director General. 3. Medical Commissioner I Financial Commissioner for information. 4. Accounts Branch- V (Hqrs. Office) 5. SSMC I SMC (All States) DY. MEDICAL CO MISSIONER (RC) ~) XI

15 Approved Vendor list SNO. FIRM NAME -- 1 Abbott Healthcare Private Limited 2 ANGLO FRENCH DRUGS AND INDUSTRIES LIMITED 3 ASTRAZENECA PHARMA INDIA LIMITED 4 Baxter (India) Pvt. Ltd. s Boehringer lngelheim Indio Pvt. Ltd. 6 CENTAUR PVT. LTD. 7 Cipla Ltd 8 Dr Reddys Laboratories Limited 9 Emcure Pharmaceuticals Limited 10 Gennova Biopharmaceuticals Limited 11 GlaxoSmithK/ine Pharmaceuticals Ltd 12 GLENMARK LIMITED 13 Hob Pharmaceuticals & Research Ltd 14 INTAS LTD 15 JUGGATPHARMA 16 Lupin Ltd. 17 MICRO LABS LTD 18 OVERSEAS HEAL Tfi CARE PVT L TO 19 PSYCHOTROPICS INDIA LIMITED 20 Sandoz Pvt. Ltd. 21 Sanofi India Limited 22 Sanofi Synthelabo {I) Pvt. Ltd. 23 SERDIA (INDIA) PVT. LTD. 24 TABLETS (INDIA) LIMITED 25 THEM IS MEDICARE LIMITED 26 TORRENT L TO 27 USV Private Limited Page 1 of 1

16 Vendor Name Abbott Healthcare Private Limited Floor 17, Godrej BI<C, Plot No. C-68, BKC, Near MCA Club, Bandra (E), Mumbai Maharashtra Tel: , Term4 Delivery within 6(six) weeks (of the actual date of & Vendor Name ANGLO FRENCH DRUGS AND INDUSTRIES LIMITED 41 3RD CROSS V BLOCK RAJAJINAGAR, SSI Area, BANGALORE I<ARNATAKA Tel: Term 4 Delivery within 6(six) weeks (of the actual date of rakesh.afdil@gmail.com & rakesh.singh@afdil.com Vendor Name ASTRAZENECA PHARMA INDIA LIMITED BLOCK N112TH FLOOR MANYATA EMBASSY BUSINESS PARK RACHENAHALLI OUTER RING ROAD BAN GALORE KARNATAKA Tel: , , Term4 Delivery within 6(six) weeks (of the actual date of institution.az@astrazeneca.com Vendor Name Baxter (India) Pvt. Ltd. 2nd Floor, Tower C, Building 8, DLF Cyber City, DLF Phase II Gurgaon Haryana Tel: , Term 4 Delivery within 6(six) weeks (of the actual date of ajay_chambyal@baxter.com baxsolutions_india@baxter.com Page 1 of7

17 Vendor Name Boehringer lngelheim India Pvt. Ltd. 1102, 11th Floor, Hallmark Business Plaza, Near Guru Nanak Hospital Road, Bandra East, Mumbai Maharashtra Tel: /78, , Term 4 Delivery within 6(six) weeks (of the actual date of sandeep.kaul@boehringer-ingelheim.com & anurag.sharma@boehringer-ingelheim.com Vendor Name CENTAUR PVT. LTD. CENTAUR HOUSE, SHANT! NAGAR, Near Grand Hyatt, VAKOLA SANTACRUZ (East), MUMBAI MAHARASHTRA Tel: /274/112, Term 4 Delivery within 6(six) weeks (of the actual date of vazirani@centaurlab.com Vendor Name Cipla Ltd Cipla Limited, Mumbai Central, Mumbai Maharastra Tel: Term 4 Delivery within 6(six) weeks (of the actual date of manojkumar.singh@cipla.com Vendor Name Dr Reddys Laboratories Limited , Ameerpet , Hyderabad Telangana Tel: Term 4 Delivery within 6(six) weeks (of the actual date of jasveerm@drreddys.com & ibtpricing@drreddys.com Page 2of7

18 Vendor Name Emcure Pharmaceuticals Limited Emcure House Plot No. 184, MIDC Bhosari Pune Maharashtra Tel: Term 4 Delivery within 6(six) weeks (of the actual date of nitin.nagar@emcure.co.in Vendor Name Gennova Biopharmaceuticals Limited Survey No. 255/2, Phase-1, Rajiv Gandhi IT Park, MIDC, Hinjwadi, Pune Tel: , , Term 4 Delivery within 6(six) weeks (ofthe actual date of rahul.k@emcure.co.in, nitin.nagar@emcure.co.in Vendor Name GlaxoSmithKiine Pharmaceuticals ltd GSK House, Dr.Annie Besant Road, Worli Mumbai Maharashtra Tel: , , Term 4 Delivery within 6(six) weeks (of the actual date of sunil.m.tawde@gsk.com & pankaj.x.popli@gsk.com Vendor Name GLEN MARK LIMITED GLEN MARK HOUSE, B D SA WANT MARG, Chakala, ANDHERI (EAST) MUMBAI MAHARASHTRA Tel: /927, , Term4 Delivery within 6(six) weeks (of the actual date of shantaram.patil2@glenmarkpharma.com Page 3 of 7

19 Vendor Name Hab Pharmaceuticals & Research Ltd 308,3rd Floor, T.V Industrial Estate S.K Ahire Marg behind Glaxo Lab, Worli Mumbai Maharashtra Tel: , , Term4 Delivery within 6(six) weeks (of the actual date of Vendor Name INTAS LTD 2nd Floor, B Wing, Corporate Office, Nr. Sola Bridge, Opp. Zydus Hospital, S.G. Highway, Ahmedabad Tel: Term 4 Delivery within 6(six) weeks (of the actual date of ketan_shah@intaspharma.com Vendor Name JUGGAT PHARMA 782, 15th Cross, I Phase, J.P. Nagar, Bangalore Bangaluru Karnataka Tel: , , , Term4 Delivery within 6(six) weeks (of the actual date of dbanerjee@jagdale.com Vendor Name Lupin Ltd. 3rd Floor, Kalpataru Inspire, Off W.E. Highway, Santacruz (East) Mumbai Maharashtra Tel: Term 4 Delivery within 6(six) weeks (of the actual date of vijaymadan@lupin.com Page 4 of7

20 Vendor Name MICRO LABS LTD No. 27, RACE COURSE ROAD, BANGALORE KARNATAKA Tel: , Term 4 Delivery within 6(six) weeks (of the actual date of rakeshsharma_micro@yahoo.co.in & shankars@microlabs.in Vendor Name OVERSEAS HEALTH CARE PVT LTD 335 KM MILESTONE, NH N0.1, P.O.BOX-25 PHILLAUR PUNJAB Tel: , , Term4 Delivery within 6(six) weeks (of the actual date of info@overseashealthcare.co.in Vendor Name PSYCHOTROPIC$ INDIA LIMITED PLOT NO. 17 SECTOR- 20 A, FARIDABAD FARIDABAD HARYANA Tel: Term4 Delivery within 6(six) weeks (of the actual date of kapoorsatish72@yahoo.com Vendor Name Sandoz Pvt. Ltd. 201, Palika Bhawan, Sector-Xiii, R.K.Puram, New Delhi Tel: , Term 4 Delivery within 6(six) weeks (ofthe actual date of rajender.arora@novartis.com & puru.gupta@novartis.com Delivery within 6(six) weeks (of the actual date of Page 5 of7

21 Vendor Name Sanofi India Limited Sanofi House, CTS No.117-B, L&T, Business Park, Saki Vihar Road, Powai, Mumbai Tel: , Term4 Vendor Name Sanofi Synthelabo {I) Pvt. Ltd. Sanofi House, CTS No.117-B, L&T, Business Park, Saki Vihar Road, Powai, Mumbai Tel: , Term4 Delivery within 6(six) weeks (of the actual date of Vendor Name SERDIA (INDIA) PVT. LTD. Serdia House, Off. Dr. S. s. Rao Road, Pare I Mumbai Maharashtra Tel: / Term4 Delivery within 6(six) weeks (of the actual date of serdia.sales@in.netgrs.com Name TABLETS (INDIA) LIMITED Vendor Jhaver Centre, IV Floor, Raja Annamalai Building, 72, Marshalls Road, Egmore, Chennai Tel: , , Term4 Delivery within 6(six) weeks (of the actual date of hd@tabletsindia.com Page 6 of7

22 Vendor Name THEMIS MEDICARE LIMITED 11/12, Udyog Nagar, SV Road, Gorefaon(West), Mumbai Tel: , Term 4 Delivery within 6(six) weeks (of the actual date of instmgr@themismedicare.com & elizabeth@themismedicare.com Vendor Name TORRENT LTD TORRENT HOUSE, OFF ASHRAM ROAD AHMEDABAD GUJARAT Tel: I 3060 Term 4 Delivery within 6{six) weeks (of the actual date of Supply!O be made directly. atulshah@torrentpharma.com & vikrampatel@torrentpharma.com Vendor Name USV Private Limited Arvind Vithhal Gandhi Chowk, B.S.D Marg, Govandi, Mumbai Maharashtra Tel: Term 4 Delivery within 6{six) weeks (of the actual date of manoj.sharma@usv.in Page 7 of7

23 RC 143 (Index) Sno. Item No. Item Name and Description Unit Page No. COUGH SYP- Each Sml to contain: Ambroxol Hydrochloride 30mg Terbutaline Sulphate eqv to Terbutaline 1.25mg, Guaiphenesin 50mg 100m I bot 1 COUGH SYP.- Each 5 ml to contain : Methdilazine 2.5 mg, Amm. Chloride mg, sodium citrate 50 mg. 115 ml Bot. 1 Ambroxol Hrdrochloride 30 MG, Terbutaline Sulphate equivalent to terbutaline 2.5 mg Tab 1tab 1 Each 5 ml Contains Ambroxol Hrdrochloride IP 30 mg Terbutaline Sulphate IP equivalent to terbutaline 2.50 mg Guaiphenesin IP 50 Mg MenthoiiP m I bott 1 INHALER- Containing: Moulded plastic device containing a foil strip with30/ 60 regularly placed blisters each containing 50 meg of salmeterol xinafoate and 250 meg of Fluticasone propionate 1 dose 2 lndacaterol maleate 143mcg eqv. to 110 meg indacaterol & 63 meg Glycopyrronium Bromide eqv to 50 meg Glycopyrronium. Cap 1 cap 2 FLUTICA50NE+5ALMETROL ROTACAP- Each rotacap to contain: Fluticasone meg+ Salmetrol 50 meg 1 cap TIOTROPIUM BROMIDE 18mcg ROTACAP 1 cap BECLOMETHASONE DIPROPIONATE IP 200MCG (HFA TECHNOLOGY) 200MDI 3 BUDESONIDE RESP.- Each 2m I to contain :Budesonide 1mg Steriod Nebulizing Fluid 2m I. amp Budesonide 0.5mg+ l.evosalbutamol1.25m!l_ Resp. 2m I amp 3 METOPROLOL ER TAB- Each ER tab to contain: Metoprolol Succinate a 47.5mg equivalent to Metoprolol Tartrate SOmg. 1 tab 4 - METOPROLOL SUCCINATE SR TAB- Each SR tab to contain: Metoprolol Succinate 23.75mg equivalent to Metoprolol Tartrate 25mg 1 tab 4 Each Prolonged Release Film coated Tablet to contain: 5(-)Metoprolol succinate mg Eqv. to 5(-) Metoprolol Tartrate 50 mg 1 tab Each Tablet to contain : S-Metoprolol 25 mg 1 tab AMIODARONE TAB- Each tab to contain: Amiodarone HCL 100mg. 1 tab AMIODARONE INJ- Each ml to contain: Amiodarone SOmg. 3ml inj TRIMETAZIDINE TAB- Each tab to contain :Trimetazidine Hcl 20 mg. 1 tab MOXON I DINE TAB- Each tab to contain: Moxonidine 0.2mg 1 tab Ticagrelor 90mg Tab 1 tab lvabradine hcl equivalent to lvabradine7.5mg Tab 1 tab Sacubitril24mg and 26mg valsartan Tab 1tab acubitril 49mg and 51mg valsartan Tab 1 tab b ENALAPRIL MALEATE 5mg TAB 1tab c RAMIPRIL 5mg TAB/CAP 1 tab/cap c PERINDOPRIL 8mg TAB 1 tab PERINDOPRIL 4mg+ INDAPAMIDE 1.25mg TAB 1 tab ATENOLOL SOmg + AMLODEPINE Smg TAB 1tab TELMISARTAN TAB- Each tab: Telmisartan 40mg 1 tab OLMESARTAN 20 mg TAB/CAP 1 tab/cap a CARVEDILOL TAB- Each Tab: Carvedilol 3.125mg. 1tab 10 Page 1 of 2

24 RC 143 {Index). Sno. Item No. Item Name and Description Unit Page No METOLAZONE TAB- Each Tab: Metolazone 5mg. ltab METOPROLOL INJ- Each mi.: Metoprolol1mg. 5ml TORSEMIDE TAB Each tab: Torsemide 10mg ltab 11 Potassium Citrate IP 1100mg, Magnesium Citrate USP 375mg, Pyridoxine HCL IP 20mg, (Each ml to contains approx lmeq Magnesium lon, 2mEq Patassium lon, 3mEq Citrate lon and 4mg of Pyridoxine HCL) in Each 5 ml 200m I batt ISOXSUPRINE INJ- Each ml to contain: lsoxsuprine 5mg. 2m I amp 11 HAEMOSTATIC TAB- Each tab. to contain: Micronized purified Flavonoid fraction of Rutaceae 500mg ltab 12 HAEMOSTATIC- Each 5ml to contain: Haemostatic Matrix with Prefilled Gelatin Granules in Syringes 5ml a ETHAMSYLATE TAB- Each Tab to contain Ethamsylate 250 mg. 1 Tab 12 FONDAPARINUX SODIUM JNJ- Each PFS to contain: Fondaparinux Sodium mg 0.5ml PFS 12 Micronised purified flavonoid fraction 1000mg composed of diosmin mg {90%) and flavonoids expressed as hesperidin 100mg (10%) Ta~-- 1 tab 13 Hemostat containing: Hemostatic matrix with thrombin in prifilled syringe m I 1 PFS CLOPJDOGREL TAB- Each tab to contain: Clopidogrel 7Smg. 1 tab TENECTEPLASE 40MG INJ 1 vial Dabigatran 110mg Cap 1 cap 14 ANTICOAGULANTS-Each Kit to contain:two componant fibrin sealant with synthetic Aprotinin (4ml) 4ml b OLANZAPINE Smg TAB 1 tab IMIPRAMINE TAB- Each tab to contain: Imipramine 25mg. 1 tab a ESCITALOPRAM 10mg TAB 1 tab b ESCITALOPRAM 20mg TAB 1 tab CITICOLINE TAB- Each tab to contain: Citicoline 500 mg ltab SULBUTIAMINE 200mg TAB 1 tab PHENYTOIN SODIUM loomg TAB 1 tab 17 SODIUM VALPROATE + VALPROIC ACID CR TAB- Each CR tab to contain: b (Sodium Valproate + Valproic Acid) eqv. to Sodium Valproate 500mg. 1 tab a CLOBAZAM TAB- Each tab to contain: Clobazam 5 mg ltab b CLOBAZAM TAB- Each tab to contain: Clobazam I.P.lO mg 1 tab OXCARBAZEPINE 150mg TAB 1 tab LEVETIRACETAM 500mg TAB 1 tab LEVETIRACETAM 250mg TAB 1 tab LAMOTRIGINE 25mg DISP. TAB 1 tab LAMOTRIGINE 100mg TAB 1 tab LITHIUM CR 450mg TAB 1 tab DIVALPROEX SOD. 250mg SR/ER/CR Tab ltab DIVALPROEX SOD. SOOmg SR/ER/CR Tab 1 tab SODIUM VALPROATE 200mg TAB 1 tab Page 2 of 2

25 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1459 COUGH SYP - Each 5ml to contain: Ambroxol Hydrochloride 30mg Terbutaline Sulphate eqv to Terbutaline 1.25mg, Guaiphenesin 50mg Menthol 0.5mg TABLETS (INDIA) LIMITED 27.1/lOOml bot 100ml bott FIRST looml bot AMBROLITE S+ SYRUP Rupees twenty seven paisa ten only 1343 COUGH SYP. - Each 5 ml to contain : Methdilazine 2.5 mg, 1115 ml Bot. / Amm. Chloride 100 mg, sodium citrate 50 mg. GlaxoSmithKiine 41.61/115 ml 115ml Bott FIRST Dilosyn Expectorant Pharmaceuticals Ltd Bot. Rul)ees forty one paisa sixty one only 2060 Each Uncoated tablet contains Arnbroxol Hrdrochloride 30 MG 1 tab Terbutaline Sulphate equivaler\t to terbutaline 2.5 mg TABLETS (INDIA) 3.41/1 tab 10 tab FIRST LIMITED Rupees three paisa forty one only AMBROLITE ST 2061 Each 5 ml Contains Arnbroxol Hrdrochloride IP 30 mg Terbutaline Sulphate IP equivalent to terbutallne 2.50 rng Guaiphenesin IP 50 MgMenthoiiP 0.5 rng loom! bott FIRST TABLETS (INDIA) LIMITED 38.38/100ml bott 100m I bott AMBROLITE 25 SYRUP Rupees thirty eight paisa thirty eight only Page 1 of 22

26 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May znd 2020 [ttem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1520 INHALER - Containing: Moulded plastic device containing a foil strip with30/ 60 regularly placed blisters each containing 50 meg of salmeterol xinafoate and 250 meg of Fluticasone propionate Glaxo5mlthKhne 5.72/1 dose 60 Bhster FIRST Pharmaceuticals Ltd 1 dose Seret1de Accuhaler 50/250 MCG Mfg.: Glaxo Wellcome Production, France Rupees five paisa seventy two only 2062 Each cap contains : 143 meg indacaterol maleate eqv. to 110 meg indacaterol & 63 meg Glycopyrronium Sromide eqv to 50 meg Glycopyrronium. Sandoz Pvt. Ltd. S3.2527/1 cap 30capand 1 inhaler FIRST 1 cap Sequadra Mfg.: Novartls Pharma Stein AG, Switzerland Rupees fifty three paisa two five two seven only 550 FLUTICASONE+SALMETROL ROTACAP - Each rotacap to 1 cap contain: Fluticasone 250 rnc + Salrnetrol 50 meg Cipla Ltd /1 cap 30 cap FIRST SEROFLO 250 ROTACAPS Rupees one paisa five nine six seven only Lupin Ltd. GLEN MARK LIMITED 1.656/1 cap 30cap SECOND Esiflo 250 Transcaps Rupees one paisa six five six only 4.23/1 cap ~0 cap THIRD AIRTEC SF 250- DPI Rupees four paisa twenty three only Page 2 of22

27 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 lttem No Firm Name I Drug Description Firm Rate/ unit Firm Packing Preference I Packing Description of stores accepted 1525 Lupin Ltd. TIOTROPIUM BROMIDE ROTACAP - Each rotacap to contain : Tiotropium Bromide I.P./BP eqv. to Tiotropium Bromide Monohydrate :L8mcg. :1.2563/1 cap 30Cap FIRST 1 cap Tlate Transcaps Rupees one paisa two five six three only Cipla ltd :1.4313/1 cap 15 cap SECOND TIOVA ROTACAPS Rupees one paisa four three one three only 2015 Cipla Ltd BECLOMETHASONE DIPROPIONATE IP 200MCG (HFA TECHNOLOGY) INHALER - Each metered dose to contain: Beclomethasone Dipropionate IP 200mcg (HFA Technology) 68.74/200MDI 200MDI FIRST 200MDI BECLATE CFC FREE INHALER200 Rupees sixty eight paisa seventy four only 1524 Cipla Ltd BUDESONIDE RESP. - Each 2ml to contain :Budesonide 1mg Steriod Nebulizing Fluid 2ml. amp. 6.48/2rnl. amp. 2 rnl FIRST BUDECORT lmg RESPULE Rupees six paisa forty eight only 2064 Each amp to contain: Budesonide O.Smg+ Levosalbutamol 2m I amp 1.25mg Cipla Ltd 19.5/2ml amp 2Ml FIRST Rupees.nineteen paisa fifty only BUDESAL O.SMG RESPULE Page 3 of 22

28 Employees' S'tate Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 525a Cipla Ltd METOPROLOL ER TAB - Each ER tab to contain: Metoprolol lltab Succinate 47.5mg equivalent to Metoprolol Tartrate SOmg /1 tab 15 tab FIRST METOLAR XR 50 I Rupees Zero paisa seven one three three only I NT AS LTD 0.95/1 tab 30tab SECOND EM BETA XR-50 Rupees zero paisa ninety five only MICRO LABS LTD 0.96/1 tab 15 tab THIRD METAPRO XL 50 Rupees zero paisa ninety six only 1845 METOPROLOL SUCCINATE SR TAB Each SR tab to contain: 1 tab Metoprolol Succinate 23.75mg equivalent to Metoprolol Tartrate 25mg Cipla ltd 0.558/1 tab 1Stab FIRST METOLAR XR 25 Rupees zero paisa five five eight only I NT AS 0.66/1 tab 30tab SECOND EM BETA XR-25 LTD Rupees zero paisa sixty six only MICRO LABS L TO 0.74/1 tab 15 tab THIRD METAPRO XL 25 Rupees zero paisa seventy four only Page 4 of22

29 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May znd 2020 [ttem No [ Drug Description [Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 2067 Each Prolonged Release Film coated Tablet to contain : S(- )Metoprolol succinate mg Eqv. to S(-) Metoprolol Tartrate 50 mg Em cure Pharmaceuticals Limited 6.97/1 tab 10tab FIRST ltab METPURE-XLSO Rupees six paisa ninety seven only I 2o6s I Each Tablet to contain : S-Metoprolol 25 mg Em cure Pharmaceuticals Limited 5.97/1 tab 10 tab FIRST Rupees five paisa ninety seven only 11 tab METPURE-XL AMIODARONE TAB - Each tab to contain: Amiodarone HCL 1 tab 100m g. MICRO LABS LTD 1.68/1 tab 10 tab FIRST AMIODAR 100 Rupees one paisa sixty eight only Cipla ltd Cipla Ltd 2.2/1 tab 10tab SECOND TACHYRA 100 Rupees two paisa twenty only I AMIODARONE INJ- Each ml to contain: Amiodarone 50mg. 13ml inj 35/3ml.inj 3 ml FIRST TACHYRA Rupees thirty five only Sanofi Synthelabo (I) Pvt. Ltd /3ml inj 3ml amp. SECOND Cordarone lnj Rupees fifty paisa eight only Page 5 of22

30 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 I Item No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1063 TRIMETAZIDINE TAB - Each tab to contain :Trimetazidine Hcl 11 tab 20mg. THEM IS MEDICARE 0.528/1 tab 10 tab FIRST THEMIDON LIMITED I Rupees zero paisa five two eight only Cipla Ltd 0.57/1 tab 10tab SECOND TRIVEDON 20 Rupees zero paisa fifty seven only SERDIA 6.429/1 tab l.o tab THIRD (INDIA) PVf LTD FLAVEDON 20 Rupees six paisa four two nine only I 1851 I MOXONIDINE TAB- Each tab to contain: Moxonidine 0.2mg MICRO LABS LTD 2.33/1 tab 10 tab FIRST I 1 tab MOXILONG 0.2 Rupees two paisa thirty three only I 2069 I Each Tab to contains:ticagrelor 90mg ASTRAZENECA 20.05/1 tab 14 tab FIRST PHARMA INDIA LIMITED I 1 tab BRILl NTA 90MG Mfg.: AstraZeneca Operations, AB Sweden Rupees twenty paisa five only Page 6 of22

31 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 lttem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 2070 Each Film Coated tab contain: lvabradine hcl equivalent to 1 tab lvabradine7.5mg SERDIA 16.99/1 tab 14 tab FIRST CORALAN 7.5mg Mfg.: (INDIA} PVT LTD Les Laboratories Servier Industries, France Rupees sixteen paisa ninety nine only 2071 Each film coated tablet contains: 24mg sacubitril and 26mg valsartan as sodium salt complex Sandoz Pvt. Ltd /1 tab 14 tab FIRST 1 tab Vymada 50mg Mfg.: Novartis Farma SpA., Italy Rupees forty four paisa eight eight five eight only!2012 Each film coated tablet contains: 49mg sacubitril and 51mg 1 tab L valsartan as sodium salt complex Sandoz Pvt. Ltd /1 tab 14 tab FIRST Vymada loomg Mfg.: Novartis Pharma Stein AG, Switzerland Rupees. forty eight paisa seven three three six only 56b ENALAPRIL MALEATE TAB - Each tab to contain: Enalapril 1 tab Maleate Smg. I NT AS 0.46/1 tab 15 tab FIRST ENAPRIL5 LTD Rupees zero paisa forty six only Dr Reddys /1 tab 15 tab SECOND Enam SMG Laboratories Limited Rupees zero paisa seven eight eight seven only Page 7 of22

32 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted /t068c / RAMIPRIL TAB/CAP- Each tab/cap to contain: Ramipril Smg. It tab/cap Cipla Ltd 1.45/1 tab/cap 10 tab FIRST RAMIPRES-5 Rupees one pais:~ forty five only Sanofi India Limited 4.49/1 tab/cap 10 tab SECOND Cardace 5 mg Rupees four paisa forty nine only MICRO LABS LTD 5.02/1 tab/cap 15 tab THIRD HOP ACE 5 Rupees five paisa two only 470c PERINDOPRIL TAB- Ea c h tab to conta.in: Perindopril Erbumi.ne 11 tab Bmg ~~--~~ SERDIA /1 tab 10 tab FIRST COVERSYL8mg (INDIA) PVT LTD Rupees eleven paisa four two nine only 1372 PERINDOPRIL+ INDAPAMIDE TAB - Each tab to contain: 1 tab Perindopril Erbumine 4rng, lndapamide 1.25mg GLEN MARK 7. 7/1 tab 10 tab LIMITED FIRST Rupees seven paisa seventy only PERIGARD DF SERDIA (INDIA) PVT LTD /1 tab 10tab SECOND COVERSYL PLUS Rupees eleven paisa four two nine only Page 8 of 22

33 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 litem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1373 ATENOLOL + AMLODEPINE TAB- Each tab to contain: Atenolol 1 tab 50mg, Am lode pine Smg Hab Pharmaceuticals 0.28/1 tab 10 x 10 tab FIRST CARDINOL PLUS & Research Ltd Rupees zero paisa twenty eight only PSYCHOTROPICS INDIA LIMITED 0.29/1 tab 14tab SECOND ETOPRESS AT 50 Rupees zero paisa twenty nine only I NT AS LTD 0.36/1 tab 15 tab TI-IIRD AMTAS-AT Rupees zero paisa thirty six only I TELMISARTAN TAB- Each tab to contain: Telmisartan 4bmg PSYCHOTROPICS 0.69/1 tab 10 tab FIRST INDIA LIMITED 11 tab TAB TELPIL40 Rupees zero paisa sixty nine only USVPRIVATE LIMITED 0.9S3/1 tab 10tab SECOND Tazloc 40mg Rupees zero paisa nine five three only Em cure Pharmaceuticals Limited 1.27/1 tab 15 tab THIRD Rupees one paisa twenty seven only TEMSAN-40 Page 9 of22

34 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 [item No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 1668 OLMESARTAN TAB/CAP- Each tab/cap to contain: Olmesartan 1 tab/cap 20m g. PSYCHOTROPIC$ 0.87/1 tab/cap 10 tab FIRST TAB OLIPIL 20 INDIA LIMITED Rupees zero paisa eighty seven only Cipla Ltd 1.25/1 tab/cap 10 tab SECOND OLMECIP 20 Rupees one paisa twenty fiv.e only USVPRIVATE LIMITED 1.59/1 tab/cap 10 tab THIRD Olmetrack 20mg Rupees one paisa fifty nine only I 336a I CARVEDILOL TAB- Each Tab to contain: Carvedilol 3.125mg. I NT AS 0.33/1 tab 15 tab FIRST LTD 11 tab CMCA Rupees zero paisa thirty three only I METOLAZONE TAB- Each lab tocontain Metolazone Smg. CENTAUR 7.5/1 tab 10 tab FIRST PVT. LTD 11 tab METOZ5 Rupees seven paisa fifty ohly Page 10 of22

35 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 lttem No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted ls74 I METOPROLOL INJ - Each mi. to contain: Metoprolollmg. Cipla Ltd 10.5/5ml 5 ml FIRST lsml METOLAR Rupees ten paisa fifty only I TORSEMIDE TAB- Each tab to contain: Torsemide 10mg MICRO LABS LTD 0.97/1 tab 10 tab FIRST 11 tab TORSINEX10 Rupees zero paisa ninety seven only Cipla Ltd /1 tab 15tab SECOND DVTOR 10 Rupees one paisa nine seven three three only 2075 Each Sml contains :Potassium Citrate IP 1100mg, Magnesium Citrate USP 375mg, Pyridoxine HCL IP 20mg, (Each ml to contains approx lmeq Magnesium lon, 2mEq Patassium lon, 3mEq Citrate lon and 4mg of Pyridoxine HCL) OVERSEAS HEALTH CAREPVTLTD 80/200ml bott 200 ml bott. FIRST 200m I bott ALKAMAXMB6 Rupees eighty only I 63 jisoxsuprine INJ - Each ml to contain: lsoxsuprine Smg. JUGGAT PHARMA 9/2ml amp 5X2ml FIRST j2mlamp Tidilan Injection Rupees nine only Page 11 of 22

36 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3'd 2018 to Saturday May 2"d 2020 lttemno I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 322 HAEMOSTATIC TAB- Each tab. to contain: Micronized purified 1 tab Flavonoid fraction of Rutaceae 500mg SERDIA 8.143/1 tab 10 tab FIRST DAFLON {INDIA) PVT LTD Rupees eight paisa one four three only 1670 HAEMOSTATIC- Each Sml to contain: Haemostatic Matrix with Sml Prefilled Gelatin Granules in Syringes Baxter (India) Pvt. Ltd 12500/5ml 5ml FIRST Floseal Mfg. Baxter Healthcare Corporation, USA Rupees twelve thousand five hundred only I 68a I ETHAMSYLATE TAB- Each Tab to contain Ethamsylate 250 mg. JUGGAT PHARMA /1 Tab 10 tab FIRST 11 Tab Botrostat Tablet Rupees four paisa six nine four one only 1536 FONDAPARINUX SODIUM INJ - Each PFS to contain: O.Sml PFS Fondaparinux Sodium 2.5mg Dr Reddys 330/0.Srnl PFS 1PF5 FIRST Fonda Red 2.5 lnj Laboratories Limited Rupees three hundred thirty only Page 12 of 22

37 Employees' State Insurance Corporation Rate Schedule of Running Rate Contract No. U-25/12/142/2017-Med V FOR RC 143 Valid from Thursday May 3rrl 2018 to Saturday May 2"d 2020 I Item No I Drug Description I Packing Firm Name Firm Rate/ unit Firm Packing Preference Description of stores accepted 2076 Each film coated tablet contains micronised - purified flavonoid fraction 1000mg composed of diosmin 900mg (90%) and flavonoids expressed as hesperidin 100mg (10%) SERDIA (INDIA) PVT LTD /1 tab 10tab FIRST 1 tab DAFLON looomg Rupees thirteen paisa two hundred fourteen only 2077 Hemostat containing: Hemostatic matrix with thrombin in prifilled syringe 10m I Baxter (India) Pvt. Ltd 21995/1 PFS 1 PFS FIRST 1 PFS Floseal Mfg. Baxter Healthcare Corporation, USA Rupees twenty one thousand nine hundred ninety five only I 429 I CLOPIDOGREL TAB- Each tab to contain: Clopidogrel75mg. I 1 tab Hab Pharmaceuticals 0.9/1 tab 10 tab FIRST LAVIX-75 & Research Ltd J Rupees zero paisa ninety only Clpla Ltd /1 tab 15 tab SECOND CLOPIVAS 75 Rupees zero paisa nine nine three three only I NT AS LTD 1.06/1 tab 15 tab THIRD CLAVIX-75 Rupees one paisa six only Page 13 of22